Announcing our latest investment led by Spectrum Equity and McKesson Ventures
RxVantage recently shared news of its latest investment directed by McKesson Ventures and Spectrum Equity. These two investors will be joining RxVantage’s existing investors, which include Merck Global Health Innovation Fund, Slater Technology Fund, Javelin Venture Partners, and dRx Capital.
RxVantage’s goal is to promote technology that allows professionals in healthcare and life science to collaborate seamlessly, safely, and effectively. Its technology allows medical practices to get important resources, wherever and whenever they are needed. The new investment is following a time of notable growth for RxVantage, in which it added more than 2,500 leading medical practices to its network. The RxVantage team has also gained more than 100 new employees through organic means thanks to its recent acquisition of onPoint Oncology.
The company plans to use this growth as an opportunity to push its provider-first approach to help healthcare professionals and life science companies partner faster in a time of quick technological innovation in the healthcare industry. The company describes its utility as powering smarter connections to build its community. RxVantage expects the new funding to aid acceleration of its vision by welcoming more medical practices and doctors into its network and providing innovations that fulfill its community’s evolving needs.
The company expressed excitement about the new investors in a recent press release, stating that it is “excited to welcome Spectrum Equity and McKesson Ventures as investors and partners. Moreover, we are excited to further our mission and find new ways to support our provider and life science communities amidst unprecedented disruptions and new engagement models.”
Read the full press release on the RxVantage blog.